Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 49,115,137*
Stock purchase warrants 370,000**
Stock options 7,298,350**
Fully diluted 55,841,591**
Cash  $19.5 million**
Debt Nil**
Trading symbol AVXL
52-week range $4.35 – $1.25*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations 1-844-689-3939
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org
*As of May 8, 2019
**As of March 31, 2018

Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)